Sign in

Mark Hitrik

Biotechnology Equity Research Associate at Stifel

Mark Hitrik is a Biotechnology Equity Research Associate at Stifel Financial, focusing on equity research for the biotechnology sector. He provides analytical coverage on companies within the biotech industry, contributing to research outputs that assist investors in evaluating emerging and established healthcare firms. Hitrik began his career in equity research and joined Stifel Financial as a research associate, advancing in the biotechnology coverage group. He maintains professional credentials applicable for equity research roles, including registration with FINRA and relevant securities licenses.

Mark Hitrik's questions to Acumen Pharmaceuticals (ABOS) leadership

Mark Hitrik's questions to Acumen Pharmaceuticals (ABOS) leadership • Q3 2024

Question

Mark Hitrik of Stifel inquired about the specifics of the data expected from the Phase I subcutaneous study of sabirnetug and asked for clarity on how the company plans to incorporate that formulation into future clinical studies.

Answer

CEO Daniel O'Connell explained that the Phase I study in healthy volunteers is designed to evaluate the pharmacokinetics (PK) and bioavailability of the subcutaneous dose compared to the intravenous (IV) version. He stated that it is premature to define the precise next steps for the subcutaneous program until they have analyzed this data.

Ask Fintool Equity Research AI